Ravit Geva

1.5k total citations
12 papers, 119 citations indexed

About

Ravit Geva is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ravit Geva has authored 12 papers receiving a total of 119 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 4 papers in Surgery and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ravit Geva's work include Hepatocellular Carcinoma Treatment and Prognosis (2 papers), Colorectal and Anal Carcinomas (2 papers) and Colorectal Cancer Treatments and Studies (2 papers). Ravit Geva is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (2 papers), Colorectal and Anal Carcinomas (2 papers) and Colorectal Cancer Treatments and Studies (2 papers). Ravit Geva collaborates with scholars based in Israel, United States and France. Ravit Geva's co-authors include Christophe Borg, Hiroki Hara, Toshihiko Doi, Zev A. Wainberg, Kei Muro, Charles S. Fuchs, Talia Golan, Shadia I. Jalal, Hyun Cheol Chung and Minori Koshiji and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Nutrients.

In The Last Decade

Ravit Geva

11 papers receiving 116 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ravit Geva Israel 6 79 46 29 28 12 12 119
Michael P. Croglio United States 5 32 0.4× 58 1.3× 68 2.3× 5 0.2× 6 0.5× 10 123
Pierre Guibert France 7 56 0.7× 21 0.5× 18 0.6× 9 0.3× 2 0.2× 14 96
Rachel Etherington United Kingdom 5 38 0.5× 12 0.3× 33 1.1× 18 0.6× 2 0.2× 7 105
Jean-Philippe Oster France 5 32 0.4× 40 0.9× 8 0.3× 14 0.5× 3 0.3× 14 112
Sofia Karageorgopoulou Greece 6 55 0.7× 17 0.4× 22 0.8× 13 0.5× 20 123
Bahar Saberzadeh-Ardestani United States 6 54 0.7× 12 0.3× 37 1.3× 13 0.5× 1 0.1× 23 139
Suha Abushamma United States 6 25 0.3× 32 0.7× 72 2.5× 2 0.1× 8 0.7× 19 128
Evelyn Fleming United States 6 65 0.8× 6 0.1× 20 0.7× 12 0.4× 6 0.5× 17 145
Oliver Seiz Germany 5 50 0.6× 12 0.3× 66 2.3× 26 0.9× 9 0.8× 6 130
Yasuhiko Suga Japan 6 34 0.4× 32 0.7× 7 0.2× 21 0.8× 1 0.1× 13 86

Countries citing papers authored by Ravit Geva

Since Specialization
Citations

This map shows the geographic impact of Ravit Geva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ravit Geva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ravit Geva more than expected).

Fields of papers citing papers by Ravit Geva

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ravit Geva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ravit Geva. The network helps show where Ravit Geva may publish in the future.

Co-authorship network of co-authors of Ravit Geva

This figure shows the co-authorship network connecting the top 25 collaborators of Ravit Geva. A scholar is included among the top collaborators of Ravit Geva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ravit Geva. Ravit Geva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Kariv, Yehuda, et al.. (2025). MRI is more accurate than FDG-PET in assessing complete response in rectal cancer patients after neoadjuvant therapy. Langenbeck s Archives of Surgery. 410(1). 106–106.
2.
Abrams, Ross A., Kathryn Winter, Karyn A. Goodman, et al.. (2024). NRG Oncology/RTOG 0848: Results after adjuvant chemotherapy +/- chemoradiation for patients with resected periampullary pancreatic adenocarcinoma (PA).. Journal of Clinical Oncology. 42(16_suppl). 4005–4005. 9 indexed citations
3.
Shapira, Shiran, Dina Kazanov, Nathan Gluck, et al.. (2021). 669 THE DARK AGE OF SINGLE ORGAN SCREENING IS OVER: CD24 IS A NOVEL UNIVERSAL PAN-CANCER BLOOD TEST FOR EARLY DETECTION OF CANCER. Gastroenterology. 160(6). S–130. 1 indexed citations
4.
Keizman, Daniel, Moshe Frenkel, Avivit Peer, et al.. (2021). Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Results of a Prospective Phase II Study. Nutrients. 13(12). 4295–4295. 15 indexed citations
5.
Goykhman, Yaacov, Richard Nakache, Ido Nachmany, et al.. (2019). Resection vs Transplant Listing for Hepatocellular Carcinoma: An Intention-to-Treat Analysis. Transplantation Proceedings. 51(6). 1867–1873. 6 indexed citations
6.
Geva, Ravit, et al.. (2017). Does residual microscopic disease after chemoradiotherapy for locally advanced rectal cancer translate into a good clinical outcome?. Colorectal Disease. 19(3). 237–242. 3 indexed citations
7.
Bang, Yung‐Jue, Kei Muro, Charles S. Fuchs, et al.. (2017). KEYNOTE-059 cohort 2: Safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer.. Journal of Clinical Oncology. 35(15_suppl). 4012–4012. 52 indexed citations
8.
Nanda, Rachita, Jennifer M. Specht, E. Claire Dees, et al.. (2017). Pembrolizumab for metastatic triple-negative breast cancer (mTNBC): long-lasting responses in the phase Ib KEYNOTE-012 study. European Journal of Cancer. 72. S38–S38. 10 indexed citations
9.
Geva, Ravit, et al.. (2015). The Predictive Role of ERCC1 Status in Oxaliplatin Based Neoadjuvant Therapy for Metastatic Colorectal Cancer (mCRC) to the Liver. Cancer Investigation. 33(4). 89–97. 4 indexed citations
10.
Lev‐Ari, Shahar, et al.. (2013). A prospective pilot clinical trial of “The work” meditation technique for survivors of breast cancer. European Journal of Integrative Medicine. 5(6). 487–494. 14 indexed citations
11.
Prenen, Hans, Ravit Geva, Hubert Piessevaux, et al.. (2011). Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer: A retrospective analysis.. Journal of Clinical Oncology. 29(15_suppl). e14095–e14095. 4 indexed citations
12.
Kraus, Sarah, Einat Shmueli, Shiran Shapira, et al.. (2008). S1128 Identification of CD24, a Novel Biomarker for the Early Detection of Colorectal Cancer (CRC), Using Peripheral Blood Mononuclear Cells. Gastroenterology. 134(4). A–184. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael P. Croglio Breakdown of academic impact, for papers by Pierre Guibert Breakdown of academic impact, for papers by Rachel Etherington Breakdown of academic impact, for papers by Jean-Philippe Oster Breakdown of academic impact, for papers by Sofia Karageorgopoulou Breakdown of academic impact, for papers by Bahar Saberzadeh-Ardestani Breakdown of academic impact, for papers by Suha Abushamma Breakdown of academic impact, for papers by Evelyn Fleming Breakdown of academic impact, for papers by Oliver Seiz Breakdown of academic impact, for papers by Yasuhiko Suga
Rankless by CCL
2026